Related Experiment Videos
[Pharmacokinetic study of cefotaxime in newborn infants and infants]
Insights
This study determined optimal intravenous cefotaxime dosing for infants and neonates with bacterial infections. Recommended dosages vary by age and prematurity to ensure effective treatment and safety.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Pediatric Infectious Diseases
- Antibiotic Therapy
Context:
- Bacterial infections in neonates and infants require careful antibiotic management.
- Intravenous cefotaxime is a common treatment, but optimal dosing in pediatric populations needs clarification.
- Understanding drug serum kinetics is crucial for establishing safe and effective therapeutic regimens.
Purpose:
- To establish appropriate dosage regimens and routes of administration for intravenous cefotaxime in neonates and infants.
- To analyze the serum kinetics, including peak concentrations and half-life, of cefotaxime in these young patient groups.
- To provide evidence-based recommendations for cefotaxime dosing to optimize treatment outcomes for pediatric bacterial infections.
Summary:
- The study investigated intravenous cefotaxime pharmacokinetics in 13 neonates and 5 infants with bacterial infections.
- Average dosages were 66.6 mg/kg/day in neonates and 62 mg/kg/day in infants, administered via bolus injections.
- Serum half-life was significantly longer in neonates (1.71 hr) compared to infants (0.45-0.50 hr), influenced by age, prematurity, and weight. Recommended dosing intervals varied: 3 injections/day for full-term neonates (0-8 days) at 75-150 mg/kg/day, 12-hour intervals for premature neonates (<8 days), and 6-hour intervals for older neonates and infants.
Impact:
- Provides crucial data for optimizing cefotaxime dosing strategies in vulnerable pediatric populations.
- Aims to improve treatment efficacy and minimize potential adverse effects associated with antibiotic therapy in neonates and infants.
- Contributes to evidence-based guidelines for managing bacterial infections in pediatric patients, particularly those requiring intensive care.
Abstract:
The serum kinetics of intravenous cefotaxime was studied in 13 neonates and 5 infants presenting with bacterial infections in order to establish the dosage and route of administration. Average dosage was 66.6 mg/kg/day in neonates and 62 mg/kg/day in infants. Cefotaxime was given intravenously in 3 daily bolus injections in infants and 2 bolus injections in neonates under 8 days of age. In infants the average serum peak was 173 mcg/ml at 15 min. Serum half-life was between 0.45 and 0.50 hr (T 1/2 beta) close to the one found in adults. In neonates the average serum peak was 106.2 mcg/ml at 35 min. Serum half-life was 1.71 hr (T 1/2 beta). It is prolonged in neonates who are younger, more premature and have a lower weight. In full term neonates, during the first 8 days, the desirable dose seems to be 75 to 150 mg/kg/day in 3 injections, according to the severity of the infection. In premature neonates under 8 days of age, the interval between injections should be increased up to 12 hrs. Finally, in full term neonates older than 8 days and in infants, one injection every 6 hours seems to be advisable.